Homologous and Heterologous Covid-19 Booster Vaccinations
Original Article
[키워드] acute respiratory syndrome
Ad26.COV2.S
Ad26.COV2.S vaccine
antibody
assigned
binding
BNT162b2
booster
Booster vaccine
Breakthrough infection
CD8+ T cell
CD8+ T-cell
clinical trial
combinations
conducted
coronavirus
coronavirus disease
dose
effective
Emergency use authorization
enrolled
had no
headache
Heterologous
homologous
humoral immunogenicity
immunogenic
Infection
injection
Injection-site pain
malaise
Moderna
mRNA vaccine
mRNA-1273
myalgia
Neutralizing antibody titer
Neutralizing titer
Open-label
participant
Pfizer–BioNTech
primary end point
pseudovirus
reactogenicity
receive
recipient
recipients
regimen
reported
Result
safety profile
SARS-CoV-2
SARS-CoV-2 D614G
T-cell Response
the United State
The United States
Trial
Vaccine
virus particles
[DOI] 10.1056/NEJMoa2116414 PMC 바로가기 [Article Type] Original Article
[DOI] 10.1056/NEJMoa2116414 PMC 바로가기 [Article Type] Original Article